Sales & Marketing News | pharmaphorum

News

Reviews underway of first drug for rare disease MOGAD

Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.

News

Bayer moves Hyrnuo into frontline lung cancer treatment

Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.

News

FDA starts review of AZ's COPD blockbuster hope

The FDA has started a priority review of AstraZeneca's first-in-class IL-33 inhibitor tozorakimab for COPD, setting up a decision in Q1 of 2027.

News

FDA makes acting CDER, CBER chiefs permanent

Michael Davis becomes the permanent head of CDER, while Karim Mikhail is confirmed as permanent CBER director and the FDA names its first AI leader.

News

Sandoz says it is entering "golden decade" in biosimilars

Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.

News

Pharma body sees 'green shoots' in UK investment

The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.

Reviews underway of first drug for rare disease MOGAD

Bayer moves Hyrnuo into frontline lung cancer treatment

FDA starts review of AZ's COPD blockbuster hope

FDA makes acting CDER, CBER chiefs permanent

Sandoz says it is entering "golden decade" in biosimilars

Pharma body sees 'green shoots' in UK investment

ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks